QC
CORT icon

Quantedge Capital’s Corcept Therapeutics CORT Stock Holding History

Quantedge Capital’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-49,000
Closed -$5.6M – 82
2025
Q1 		$5.6M Buy
49,000
+44,200
+921% +$2.69M 1.77% 18
2024
Q4 		$242K Buy
+4,800
New +$252K 0.09% 122
2024
Q3 		– Sell
-25,842
Closed -$840K – 189
2024
Q2 		$840K Sell
25,842
-154,800
-86% -$4.24M 0.3% 85
2024
Q1 		$4.55M Sell
180,642
-67,700
-27% -$1.6M 1.91% 17
2023
Q4 		$8.07M Buy
+248,342
New +$6.82M 3.94% 4
2023
Q2 		– Sell
-54,512
Closed -$1.18M – 136
2023
Q1 		$1.18M Sell
54,512
-196,800
-78% -$4.31M 0.46% 59
2022
Q4 		$5.1M Buy
251,312
+7,600
+3% +$191K 1.71% 12
2022
Q3 		$6.25M Sell
243,712
-80,700
-25% -$2.16M 1.93% 5
2022
Q2 		$7.71M Buy
324,412
+211,400
+187% +$4.61M 1.56% 11
2022
Q1 		$2.54M Buy
113,012
+97,700
+638% +$2.08M 0.75% 43
2021
Q4 		$303K Buy
+15,312
New +$311K 0.13% 153

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Quantedge Capital's CORT Position: Q2 2025 in Review

Quantedge Capital sold out of Corcept Therapeutics (CORT) in Q2 2025, closing a stake of 49,000 shares — an estimated $5.6M sold.

Quantedge Capital first reported a position in CORT in Q4 2021 and held it in 11 quarters. The position peaked at $8.07M in Q4 2023. 422 funds tracked by Wall St. Rank hold CORT as of Q2 2025.

  • Quantedge Capital reported no remaining Corcept Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Quantedge Capital sold 49,000 Corcept Therapeutics shares in Q2 2025, an estimated $5.6M.
  • Quantedge Capital first reported a position in Corcept Therapeutics in Q4 2021 and held it in 11 quarters.
  • Quantedge Capital's Corcept Therapeutics position peaked at $8.07M in Q4 2023.
  • 422 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2025.

Based on Quantedge Capital's 13F filing for Q2 2025, filed 14 Aug 2025.